CASE REPORT

Rare type of bladder cancer: Malignant fibrous histiocytoma

Orcun Celik, Hakan Turk, Salih Budak, Yusuf Ozlem Ilbey
Tepecik Educational and Research Hospital, Urology Clinic, Izmir, Turkey

Summary
Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma in adults. Urinary tract is a very rare location for MFH. Involvement of the bladder is more common in males and at the 6th decade of life.
A case of MFH of the bladder with poor prognosis is presented. Prognostic factors for MFH are tumor grade, amount of invasion, age, tumor size, and histological type. Survival rate is very low and 3-year disease specific survival is approximately 40%.

KEY WORDS: Malignant fibrous histiocytoma; Bladder; Tumour.
Submitted 28 April 2014; Accepted 31 May 2014

INTRODUCTION
Malignant fibrous histiocytoma (MFH) is a mesenchymal tumor, which was described by O'Brien and Stout in 1964 (1). MFH is an aggressive tumor with fusiform cells that is the most common soft tissue sarcoma in adults (2). Urinary tract, especially bladder is a very rare location for MFH with only 29 previously reported cases. Involvement of the bladder is more common in males and at the 6th decade of life. Clinical presentation is similar to other bladder tumors. In the bladder this mesenchymal tumor and its variants should be distinguished with immunohistochemical methods from sarcomatoid carcinoma, inflammatory myofibroblastic tumor and leiomyosarcoma (3). MFH spreads fast and is generally metastatic. Size, depth and histologic features of the tumor are important factors for metastasis (4). Because of its rapid local and distal metastatic character, radical cystectomy, lymph node dissection and adjuvant radiotherapy are the first line treatments (5, 6). Despite this treatment, 3-year survival is approximately 40%. This is probably due to its low frequency and lack of consensus on treatment. In the current article, we aim to review the relevant literature in the light of a case.

DISCUSSION
MFH as a common soft tissue sarcoma in adults that constitutes 10-21% of all sarcomas. It is observed more commonly in lower extremities (50%), upper extremities (20%) and retroperitoneal space (15%). It is rare in the urinary tract and if seen, it is located mostly in the kidneys. Non-epithelial tumors of the bladder consist of 2% of all bladder tumors and mesenchymal tumors of the bladder consist of 0.23-0.67% of all bladder tumors (7). MFH in the bladder is more common in males (4:1) and at the 6th decade of life and commonly presents with macroscopic hematuria. Some experts suggested that it is related to radiotherapy and chemotherapy and it often co-occurs (approximately 13%) with other tumors (leukemia, Hodgkin lymphoma, multiple myeloma) (5, 8). MFH in bladder presents as a large-sized tumor, with diameter of approximately 6.4 cm (1-15 cm). In our case, the diameter of tumor was 10 cm and extracted material was 30 cc. At diagnosis, 16% of patients are T2, 72% of patients T3 and 14% T4 (9). Disease specific survival is 47.8% at 1 year and 31.9% at 2 years (9). As it is an aggressive and rare type of tumor and there is limited number of studies, treatment is not very successful. There are mainly four morphological types (3): 1) inflammatory type (36%), 2) storiform-fascicular type (40%), 3) pleomorphic type (13%) and 4) myxoid type (9%) (10). At immunohisto-
chemical evaluation, it is vimentin, alpha-1 antichymotrypsin and factor I3A positive. In our case, the tumor was positive for vimentin and CD68.

CONCLUSION

MFH in the bladder is a rare tumor and there are approximately 29 cases reported in the literature. It presents with macroscopic hematuria and is more common in men and in the 6th decade of life. The tumor is generally large and locally advanced or metastatic like in our case. Survival rate is low and there is no consensus on treatment strategies. Histochemical evaluation is needed to distinguish MFH that has four morphological variants from similar tumors. Prognostic factors for MFH are tumor grade, amount of invasion, age, tumor size, and histological type. Because of its aggressive characteristics, local and distant metastases are likely. Therefore, cystectomy and lymph node dissection and further adjuvant radiotherapy to prevent local recurrence and adriamycin chemotherapy for distant metastasis can be used. However, there is no consensus on treatment strategies (11). Survival rate is very low and 3-year disease specific survival is approximately 40% (9). Further studies are needed in this topic.

REFERENCES


Correspondence

Orcun Celik, MD (Corresponding Author)
orcuncelik82@hotmail.com
Hakan TURK, MD
Salih Budak, MD
Yusuf Ozlem Ilbey, MD
Tepecik Educational and Research Hospital, Urology Clinic
35140 Izmir, Turkey